KalVista Pharmaceuticals, Inc.
KALV$440M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaFRAMINGHAM270 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
KALV News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
KVD900 300 mg
Hereditary Angioedema
KVD900 600 mg
Hereditary Angioedema
KVD001 Injection
Diabetic Macular Edema
KVD900
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KVD900 300 mg | Phase 3 | Hereditary Angioedema | - | - |
KVD900 600 mg | Phase 3 | Hereditary Angioedema | - | - |
KVD001 Injection | Phase 2 | Diabetic Macular Edema | - | - |
KVD900 | Phase 2 | Hereditary Angioedema | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply